Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Refractory mCRC (ABACO)
NCT06171854Phase 2Active, not recruiting
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Sep 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in metastatic colorectal cancer (mCRC), sponsored by University of Campania Luigi Vanvitelli. Primary endpoint: Progression Free Survival at 16 weeks. Started Sep 2019; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06171854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171854.